*Include 3 bullets (< 30 words total) per slide – the most important messages associated with the particular slide*

Team name: ME Therapeutics Inc.
Date updated: September 1, 2019

| | |
|---|---|
| S1: Title & Elevator Pitch/Headline | • MAKING COLON CANCER RESPONSIVE TO IMMUNO-ONCOLOGY (IO)<br>• IO has revolutionized cancer treatment but doesn't work in colon cancer<br>• Our treatment can make colon cancer responsive to IO |
| S2: The problem and who has it | • Colorectal cancer has a high incidence world-wide<br>• Metastatic CRC has a poor 5-year survival rate<br>• IO is not effective against metastatic CRC |
| S3: The solution | • IO has proven effective against some late stage cancers<br>• The immunosuppressive environment created by G-CSF may make CRC resistant to IO<br>• New combination IO therapy is required to cure CRC |
| S4: Product (how it addresses the problem) | • Developed a biological drug to block G-CSF-induced tumor immunosuppression<br>• We have patented the only drug targeting G-CSF in cancer<br>• Currently being tested alone and in combination with current IO |
| S5: Technology | • G-CSF promotes an immunosuppressive tumor environment and metastases<br>• High G-CSF expression is associated with poor prognosis in clinic<br>• Blocking G-CSF is safe and improves anti-cancer responses |
| S6: Competing approaches | • Standard of care – chemo +/- currrent targeted therapy – are not curative<br>• IO monotherapy is ineffective with only 5% of patients responding<br>• Combo IO with CSFR1 targeting drugs are not effective |
| S7: Traction | • Several key publications demonstrate the importance of G-CSF as a target in CRC<br>• Worldwide patent is filed<br>• Science validated by academic grant funding and support from oncologists at BC Cancer agency |
| S8: Team | • Founders have > 90 scientific publications & patents and >$2 million in funding<br>• Member of MIT IDEA2 Startup Incubator Program<br>• Recipient of 2019 Innovation To Commercialization Competition Award |
| S9: Closing | • CRC represents a huge unmet need<br>• New IO therapies are required for CRC – none successful so far<br>• Blocking G-CSF may unleash potential of IO therapy to cure CRC |